insights_auto
Miks on 4142 langenud? 6,62%?
Uurige põhjalikumaltchevron_right
4142:TPE
Adimmune Corp
14,80Â NT$
arrow_downward
−6,62%(−1,05) 1 p
20. nov, 13:30:09 GMT +8 · TWD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4142 põhistatistika genereerimine…
Ava
15,75Â NT$
Kõrge
15,75Â NT$
Madal
14,80Â NT$
Turu kapit.
6,36Â mld
Keskm. maht
1,13Â mln
Maht
1,63Â mln
Hinna ja tulu suhe
85,76
52 näd kõrgeim
21,50Â NT$
52 näd madalaim
14,80Â NT$
Aktsiatulu
0,17Â NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Ava
15,75Â NT$
Kõrge
15,75Â NT$
Madal
14,80Â NT$
Turu kapit.
6,36Â mld
Keskm. maht
1,13Â mln
Maht
1,63Â mln
Hinna ja tulu suhe
85,76
52 näd kõrgeim
21,50Â NT$
52 näd madalaim
14,80Â NT$
Aktsiatulu
0,17Â NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Uudised
Veebiallikatest ja uudistepartneritelt
WSJ
·
2 päeva eest
Dow, S&P 500 Poised to Close at a Correction
The Motley Fool
·
6 tunni eest
The S&P 500 Is 14 for 14 After Midterm Elections. Here’s How I’d Invest Now.
24/7 Wall St.
·
17 tunni eest
His Indexed Annuity Tracks the S&P 500. The Fine Print Says "Price Return," Which Means It Leaves Out Every Dividend the 500 Companies Pay
Traders Union
·
1 päeva eest
VIX tõusis kõrgeimale tasemele alates 2025. aasta aprillist, S&P 500 langes järsult
Profiil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Teave üksuse Adimmune Corp kohta